Crossref
For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?
Cochrane Clinical Answers · 2026-07-29
DOI: 10.1002/cca.4802 ↗At a glance
Journal article in Cochrane Clinical Answers, published online on 2026-07-29. Written by Heather Walker. 10 references.
Topics: Diabetes mellitus
Abstract (original language)
Ebda abstract disponibbli.
Cite
APA
Walker, H. (2026). For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4802
Vancouver
Walker H. For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4802
BibTeX
@article{Walker2026,
author = {Walker, Heather},
title = {For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?},
journal = {Cochrane Clinical Answers},
year = {2026},
doi = {10.1002/cca.4802}
}
EUVIMED